Get the Stockscreener App
5.64
1.99%
0.11
After Hours:
5.63
-0.010
-0.18%
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $5.64, with a volume of 1.25M.
It is up +1.99% in the last 24 hours and up +5.42% over the past month.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
See More
Previous Close:
$5.53
Open:
$5.55
24h Volume:
1.25M
Relative Volume:
0.64
Market Cap:
$2.11B
Revenue:
$10.53B
Net Income/Loss:
$-1.23B
P/E Ratio:
-1.7375
EPS:
-3.246
Net Cash Flow:
$949.99M
1W Performance:
-0.53%
1M Performance:
+5.42%
6M Performance:
-16.81%
1Y Performance:
+14.40%
1-Day Range:
$5.55
$5.73
1-Week Range:
$5.38
$6.29
52-Week Range:
$4.41
$8.685
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
5.64 | 2.07B | 10.53B | -1.23B | 949.99M | -3.246 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Bausch Health (BHC) Q1 2026 Earnings Transcript - AOL.com
Bausch Health Companies Inc. (NYSE:BHC) Q1 2026 Earnings Call Transcript - Insider Monkey
Bausch Health Companies Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:BHC) 2026-05-04 - Seeking Alpha
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - GlobeNewswire Inc.
MSN Money - MSN
Bausch Health rises on Q1 double beat, 2026 guidance - MSN
Bausch Health reaffirms 2026 guidance of $5.250B-$5.400B revenue and $2.875B-$2.950B adjusted EBITDA as tariffs are built in - MSN
Bausch Health Companies Q1 2026 Results: Revenue Up 12%, EPS Beats ForecastsNews and Statistics - IndexBox
symbol__ Stock Quote Price and Forecast - CNN
Why Bausch Health Companies was crawling higher this week - MSN
Why Bausch Health Companies Was Crawling Higher This Week - The Globe and Mail
Bausch Health Companies Inc. Q1 2026 Quarterly Report Highlights Financial Performance, Risks, and Forward-Looking Statements - Minichart
Bausch Health Cos (NYSE:BHC) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Bausch Health Rises on Strong 1Q Segment Growth, Revenue Beat - Moomoo
BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength - The Globe and Mail
RBC Keeps Sector Perform Rating, US$9.00 Price Target, on Bausch Health After Strong Q1 - marketscreener.com
RBC Capital Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Bausch Health Cos Q1 Earnings Call Highlights - MarketBeat
Bausch Health (BHC) Lags Q1 Earnings Estimates - Yahoo Finance
Compared to Estimates, Bausch (BHC) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Bausch Health Companies Inc. (BHC) stock rises on Q1 2026 Earnings - Quiver Quantitative
Bausch Health Cos (NYSE:BHC) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Earnings call transcript: Bausch Health beats Q1 2026 earnings estimates - Investing.com UK
Earnings call transcript: Bausch Health beats Q1 2026 earnings estimates By Investing.com - Investing.com Australia
Bausch: Q1 Earnings Snapshot - KVUE
[10-Q] Bausch Health Companies Inc. Quarterly Earnings Report - Stock Titan
BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS - Cantech Letter
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Bausch Health earnings on deck: Debt and patent strategy in focus By Investing.com - Investing.com Australia
Bausch Health earnings on deck: Debt and patent strategy in focus - Investing.com Australia
Bausch Health Companies Inc (BHC) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Bausch Health Companies (TSE:BHC) Stock Price Down 0.9%Time to Sell? - MarketBeat
Oaktree Capital Maintains Stake in Bausch Health Companies - HarianBasis.co
Bausch Health Companies Inc. (BHC): Billionaire Howard Marks Likes This Pharma Stock - Insider Monkey
Bausch Health falls on phase 3 failure of liver disease complications drug - MSN
RBC Cuts Price Target on Bausch Health to $9 From $10, Keeps Sector Perform Rating - marketscreener.com
RBC Capital lowers Bausch Health stock price target ahead of earnings - Investing.com Nigeria
Bausch Health Companies Q1 2025 Earnings Preview - MSN
Bausch Health to redeem ~$602M of outstanding notes due 2026 - MSN
Bausch Health rises after $300M worth insider purchase (update) - MSN
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):